Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth

Cancer Research

Volumn 64, Issue 1, 2004, Pages 236-242

  Girnita, Ada ^a   Girnita, Leonard ^a   Del Prete, Fabrizio ^c   Bartolazzi, Armando ^a   Larsson, Olle ^a,b   Axelson, Magnus ^b  

^a Karolinska Krankenhaus   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLOLIGNAN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PICROPODOPHYLLIN; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RODENT; TUMOR REGRESSION; XENOGRAFT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LIGNANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHORYLATION; PHOSPHOTYROSINE; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED;

EID: 1642494838     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2522     Document Type: Article

References (37)

1. Baserga, R. The insulin-like growth factor 1 receptor: a key to tumor growth? Cancer Res., 55: 249-252, 1995.
2. Baserga, R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene, 19: 5574-5581, 2000.
3. Girnita, L., Girnita, A., and Larsson, O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA, 100: 8247-8252, 2003.
4. Girnita, L., Gimita, A., Brodin, B., Xie, Y., Nilsson, G., Dricu, A., Lundeberg, J., Wejde, J., Bartolazzi, A., Wiman, K. G., and Larsson, O. Increased expression of insulin-like growth factor 1 receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res., 60: 5278-5283, 2000.
5. Yu, H., and Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 92: 1472-1489, 2000.
6. LeRoith, D., Werner, H., Beitner-Johnson, D., and Roberts, C. T., Jr. Molecular and cellular aspects of the insulin-like growth factor 1 receptor. Endocr. Rev., 16: 143-163, 1995.
7. Ullrich, A., Gray, A., Tam, A. W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le Bon, T., Kathuria, S., Chen, E., et al. Insulin-like growth factor 1 receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5: 2503-2512, 1986.
8. Navarro, M., and Baserga, R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology, 142: 1073-1081, 2001.
9. Favelyukis, S., Till, J. H., Hubbard, S. R., and Miller, W. T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol., 8: 1058-1063, 2001.
10. Blum, G., Gazit, A., and Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry, 39: 15705-15712, 2000.
11. Parang, K., Till, J. H., Ablooglu, A. J., Kohanski, R. A., Hubbard, S. R., and Cole, P. A. Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol., 8: 37-41, 2001.
12. Kanter-Lewensohn, L., Girnita, L., Girnita, A., Dricu, A., Olsson, G., Leech, L., Nilsson, G., Hilding, A., Wejde, J., Brismar, K., and Larsson, O. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol. Cell. Endocrinol., 165: 131-137, 2000.
13. Axelson, M., Sjövall, J., Gustafsson, B. E., and Setchell, K. D. Origin of lignans in mammals and identification of a precursor from plants. Nature (Lond.), 298: 659-660, 1982.
14. Axelson, M., Sjövall, J., Gustafsson, B. E., and Setchell, K. D. Soya-a dietary source of the non-steroidal oestrogen equol in man and animals. J. Endocrinol., 102: 49-56, 1984.
15. Kelly, M. G., and Hartwell, J. L. The biological effects of and the chemical composition of podophyllin. J. Natl. Cancer Inst., 14: 967-1011, 1954.
16. Greenspan, E. M., Colsky, J., Schoenbach, E. B., and Sherar, M. J. Response of patients with advanced neoplasms to the intravenous administration of α-peltatin. J. Natl. Cancer Inst., 16: 1257-1275. 1954.
17. Kelleher, J. K. Tubulin binding affinities of podophyllotoxin and colchicine analogues. Mol. Pharmacol., 13: 232-241, 1977.
18. Seidlova-Masinova, V., Malinsky, J., and Santavy, F. The biological effects of some podophyllin compounds and their dependence on chemical structure. J. Natl. Cancer Inst., 18: 359-371, 1957.
19. Ayres, D. C., and Loike, J. D. Lignans. Chemical, biological and clinical properties. Cambridge 121: Cambridge University Press, 1990.
20. Carter, S. K., and Slavik, M. Investigational drugs under study by the United States National Cancer Institute. Cancer Treat. Rev., 3: 43-60, 1976.
21. Hande, K. R. Eloposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 34: 1514-1521, 1998.
22. Long, B. H., Musial, S. T., and Brattain, M. G. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP-16-213 and VM-213: A quantitative structure-activity relationship. Biochemistry, 23: 1183-1188, 1984.
23. Hartwell, J. L., and Schrecker, A. W. The chemistry of podophyllum. Progr. Chem. Org. Nat. Prod., 15: 83-166, 1958.
24. Buchardt, O., Jensen, R. B., Hansen, H. F., Nielsen, P. E., Andersen, D., and Chinoin, I. Thermal chemistry of podophyllotoxin in ethanol and a comparison of the cytostatic activity of the thennolysis products. J. Pharm. Sci., 75: 1076-1080, 1986.
25. Rubini, M., Hongo, A., D'Ambrosio, C., and Baserga, R. The IGF-1 receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res., 230: 284-292, 1997.
26. Valentinis, B., Morrione, A., Taylor, S. J., and Baserga, R. Insulin-like growth factor 1 receptor signaling in transformation by src oncogenes. Mol. Cell. Biol., 17: 3744-3754, 1997.
27. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
28. Mandal, M., Vadlamudi, R., Nguyen, D., Wang, R. A., Costa, L., Bagheri-Yarmand, R., Mendelsohn, J., and Kumar, R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem., 276: 9699-9704, 2001.
29. Parrizas, M., Gazit, A., Levitzki, A., Wertheimer, E., and LeRoith, D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology, 138: 1427-1433, 1997.
30. Roehm, N. W., Rodgers, G. H., Hatfield, S. M., and Glasebrook, A. L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods, 142: 257-265, 1991.
31. Laird, A. D., Vajkoczy, P., Shawvcr, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., Fong, T. A., Strawn, L. M., Sun, L., Tang, C., Hawtin, R., Tang, F., Shenoy, N., Hirth, K. P., McMahon, G., and Cherrington SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 60: 4152-4160, 2000.
32. PCT WO 02/102904 A1 (27.12.2002): New use of specific cyclolignans.
33. PCT WO 02/102805 A1 (27.12.2002): New use of cyclolignans and new cyclolignans.
34. Bayes-Genis, A., Conover, C. A., and Schwartz, R. S. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ. Res., 86: 125-130, 2000.
35. Patel, V. A., Zhang, Q. J., Siddle, K., Soos, M. A., Goddard, M., Weissberg, P. L., and Bennett, M. R. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ. Res., 88: 895-902, 2001.
36. Wraight, C. J., White, P. J., McKean, S. C., Fogarty, R. D., Venables, D. J., Liepe, I. J., Edmondson, S. R., and Werther, G. A. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor 1 receptor antisense oligonucleotides. Nat. Biotechnol., 18: 521-526, 2000.
37. Colao, A., Cuocolo, A., Marzullo, P., Nicolai, E., Ferone, D., Della Morte, A. M., Pivonello, R., Salvatore, M., and Lombardi, G. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor 1 levels on cardiac performance. J. Clin. Endocrinol. Metab., 86: 1551-1557, 2001.